Home | Welcome to Contract Pharma   
Last Updated Saturday, July 12 2014
Print

Search Results for 'Financial Report: GlaxoSmithKline'

Search For:
Refine by Dates:
From: To:
Past 7 Days        Past 30 Days
Refine By Content:

Search Results:

Published October 23, 2013
Bribery allegations impact sales in China Read More »
Published July 24, 2013
Revenues fall flat in the quarter Read More »
Published February 6, 2013
Revenues decline 3% in the quarter, new change program accelerates Read More »
Published February 7, 2012
Vaccines sales drop 19% in 2011 Read More »
By Gil Roth
Published July 26, 2011
Avandia, Valtrex and pandemic losses reduce revenues Read More »
Published April 27, 2011
Pharmaceutical sales were $8.4 billion in the quarter (-12%). Read More »
Published April 28, 2010
Growth in the quarter was driven by pandemic flu vaccine sales. Total vaccine sales were $2.1 billion, including $1.1 billion of H1N1 vaccine sales. Read More »
Published February 9, 2006
GlaxoSmithKline 4Q Revenues: $10.3 billion (+13%) 4Q Earnings: $1.9 billion (+45%) FY Revenues: $37.8 billion (+8%) FY Earnings: $8.2 billion (+20%) Comments: Growth driven by key products: Seretide/Advair, Avandia and the compan… Read More »
By Kristin Brooks
Published March 7, 2014
Hall brings 30 years of R&D experience Read More »
By Kristin Brooks
Published January 3, 2014
Allows researchers to access sponsor clinical data Read More »
Receive free Contract Pharma Direct emails
Sign up now to receive the weekly newsletter, and more!

Enter your email address:
Follow Contract Pharma On